Dr. Sylvia Adams, MD

Dr. Adams practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Dr. Adams' NPI, 1881767903, was assigned on November 16, 2006. Dr. Adams graduated from Friedrich-Schiller-Universität Jena in 1995. Dr. Adams holds New York license 217787.

Dr. Adams' primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Dr. Adams' primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Adams to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Adams practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Adams' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Adams is board certified in medical oncology by the American Board of Internal Medicine. Dr. Adams is licensed in New York.

Dmand AI lists breast cancer and lung cancer among the conditions Dr. Adams treats.

CMS data shows 84 Medicare services from Dr. Adams across 3 procedure codes in 2024, all of them office visits, for 67 Medicare patients. Medicare paid $5,468 for them. Every service was in an office.

CMS counts 67 Medicare patients who saw Dr. Adams in 2024. The largest group is 65 to 74, with 32 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Adams' median patient age at 67, with 96% women.

In 2024, Dr. Adams wrote 42 Medicare Part D claims for 20 patients. 100% of them were for generic drugs. CMS names the drug for 23 of them, across 1 drug with 11 or more claims each, at $400 in total drug cost. In 2023, CMS named 73 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Adams for performance year 2024, reported as part of a group.

Dmand AI links 135 papers to Dr. Adams, published from 2004 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Breast Neoplasms, Triple Negative Breast Neoplasms and Amino Acid Sequence. Dr. Adams has published most often in Proc Natl Acad Sci U S A. Dr. Adams' most frequent co-authors are Sunil Badve, MD, Hope S. Rugo, MD and Silvia C. Formenti, MD.

Dmand AI links Dr. Adams to 9 clinical trials, 3 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Melanoma. NYU Langone Health sponsors the most, 5.

CMS Open Payments shows 34 general payments to Dr. Adams from 6 drug and device companies from 2016 to 2021. Speaker and faculty fees make up the largest share, 73% of the total. Genentech, Inc. paid the most, $29,592. It also lists 11 research payments totaling $11,065 from 2020 to 2021.

Dr. Adams graduated from Friedrich-Schiller-Universität Jena in 1995.

Dr. Adams is in network with 14 carriers, including Elevance, United Healthcare and HCSC. HMO plans come from the most carriers, 8. Check the plan with the practice before a visit.